MSB 8.42% $1.03 mesoblast limited

Overwhelming efficacy - the stats required, page-495

  1. Yor
    150 Posts.
    lightbulb Created with Sketch. 70
    @kervio thank you for taking the time to explain this in details. A couple of remarks: the trial is powered now with 21 hospitals, up from 15 in August, and has enrolled 50% in mid October. We may hope that 60% enrollment would be achieved in November when the DSMB will come up with the 45% interim analysis. Also, as you pointed out, SOC ensures better results as 65% of ventilated patients decease down from 85% in April, about 20% improvement. I feel this may help not only placebo but maybe also the patients who receive the treatment. If we improve by the same proportion, 20%, we would be closer to 80% than 75% (9/12) survival rate. This in turn affects the differential.
    Let’s hope, and be patient
    GL all
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.03
Change
0.080(8.42%)
Mkt cap ! $1.176B
Open High Low Value Volume
95.5¢ $1.03 95.0¢ $43.38M 42.28M

Buyers (Bids)

No. Vol. Price($)
4 72752 $1.01
 

Sellers (Offers)

Price($) Vol. No.
$1.03 205100 2
View Market Depth
Last trade - 16.10pm 30/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.